BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 26830551)

  • 21. Dilative arteriopathy and basilar artery dolichoectasia complicating late-onset Pompe disease.
    Laforêt P; Petiot P; Nicolino M; Orlikowski D; Caillaud C; Pellegrini N; Froissart R; Petitjean T; Maire I; Chabriat H; Hadrane L; Annane D; Eymard B
    Neurology; 2008 May; 70(22):2063-6. PubMed ID: 18505979
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Auditory system involvement in late onset Pompe disease: a study of 20 Italian patients.
    Musumeci O; Catalano N; Barca E; Ravaglia S; Fiumara A; Gangemi G; Rodolico C; Sorge G; Vita G; Galletti F; Toscano A
    Mol Genet Metab; 2012 Nov; 107(3):480-4. PubMed ID: 22958975
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Restrictive Arteriopathy in Late-Onset Pompe Disease: Case Report and Review of the Literature.
    Malhotra K; Carrington DC; Liebeskind DS
    J Stroke Cerebrovasc Dis; 2017 Aug; 26(8):e172-e175. PubMed ID: 28647415
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An integrative correlation of myopathology, phenotype and genotype in late onset Pompe disease.
    Kulessa M; Weyer-Menkhoff I; Viergutz L; Kornblum C; Claeys KG; Schneider I; Plöckinger U; Young P; Boentert M; Vielhaber S; Mawrin C; Bergmann M; Weis J; Ziagaki A; Stenzel W; Deschauer M; Nolte D; Hahn A; Schoser B; Schänzer A
    Neuropathol Appl Neurobiol; 2020 Jun; 46(4):359-374. PubMed ID: 31545528
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The value of muscle biopsies in Pompe disease: identifying lipofuscin inclusions in juvenile- and adult-onset patients.
    Feeney EJ; Austin S; Chien YH; Mandel H; Schoser B; Prater S; Hwu WL; Ralston E; Kishnani PS; Raben N
    Acta Neuropathol Commun; 2014 Jan; 2():2. PubMed ID: 24383498
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bright tongue sign in patients with late-onset Pompe disease.
    Karam C; Dimitrova D; Yutan E; Chahin N
    J Neurol; 2019 Oct; 266(10):2518-2523. PubMed ID: 31256280
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A study on the safety and efficacy of reveglucosidase alfa in patients with late-onset Pompe disease.
    Byrne BJ; Geberhiwot T; Barshop BA; Barohn R; Hughes D; Bratkovic D; Desnuelle C; Laforet P; Mengel E; Roberts M; Haroldsen P; Reilley K; Jayaram K; Yang K; Walsh L;
    Orphanet J Rare Dis; 2017 Aug; 12(1):144. PubMed ID: 28838325
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The new era of Pompe disease: advances in the detection, understanding of the phenotypic spectrum, pathophysiology, and management.
    Kishnani PS; Beckemeyer AA; Mendelsohn NJ
    Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):1-7. PubMed ID: 22253049
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Correlation of acid alpha-glucosidase and glycogen content in skin fibroblasts with age of onset in Pompe disease.
    Umapathysivam K; Hopwood JJ; Meikle PJ
    Clin Chim Acta; 2005 Nov; 361(1-2):191-8. PubMed ID: 15993875
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potential patient screening for late-onset Pompe disease in suspected sleep apnea: a rationale and study design for a Prospective Multicenter Observational Cohort Study in Japan (PSSAP-J Study).
    Yamauchi M; Nakayama H; Shiota S; Ohshima Y; Terada J; Nishijima T; Kosuga M; Kitamura T; Tachibana N; Oguri T; Shirahama R; Aoki Y; Ishigaki K; Sugie K; Yagi T; Muraki H; Fujita Y; Takatani T; Muro S
    Sleep Breath; 2021 Jun; 25(2):695-704. PubMed ID: 32808237
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalence of adult Pompe disease in patients with proximal myopathic syndrome and undiagnosed muscle biopsy.
    Golsari A; Nasimzadah A; Thomalla G; Keller S; Gerloff C; Magnus T
    Neuromuscul Disord; 2018 Mar; 28(3):257-261. PubMed ID: 29326002
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnosis of late-onset Pompe disease and other muscle disorders by next-generation sequencing.
    Lévesque S; Auray-Blais C; Gravel E; Boutin M; Dempsey-Nunez L; Jacques PE; Chenier S; Larue S; Rioux MF; Al-Hertani W; Nadeau A; Mathieu J; Maranda B; Désilets V; Waters PJ; Keutzer J; Austin S; Kishnani P
    Orphanet J Rare Dis; 2016 Jan; 11():8. PubMed ID: 26809617
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reveglucosidase alfa (BMN 701), an IGF2-Tagged rhAcid α-Glucosidase, Improves Respiratory Functional Parameters in a Murine Model of Pompe Disease.
    Peng J; Dalton J; Butt M; Tracy K; Kennedy D; Haroldsen P; Cahayag R; Zoog S; O'Neill CA; Tsuruda LS
    J Pharmacol Exp Ther; 2017 Feb; 360(2):313-323. PubMed ID: 27856936
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical manifestations and acid alpha-glucosidase mutation characterisation of a cohort of patients with late-onset Pompe disease in eastern China.
    Zhao HH; Ma Z; Ying ZX; Niu FN; Luo MT; Wang Z; Cheng X; Zhang QQ; Niu Q
    Ann Transl Med; 2021 Dec; 9(24):1803. PubMed ID: 35071497
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Screening for late-onset Pompe disease in Internal Medicine departments in Spain.
    López-Rodríguez M; Torralba-Cabeza MA; de Pedro IP; Rivera A; Gil RS; Gómez-Belda A; de la Peña JLP; de Los Santos Moreno A; Selva-O'Callaghan A; Gárate IG; García AG; Hurtado R; de Ureta PT; Barba-Romero MÁ; Milisenda JC; Grau-Junyent JM;
    Orphanet J Rare Dis; 2023 Aug; 18(1):256. PubMed ID: 37653444
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expanding the clinical spectrum of late-onset Pompe disease: dilated arteriopathy involving the thoracic aorta, a novel vascular phenotype uncovered.
    El-Gharbawy AH; Bhat G; Murillo JE; Thurberg BL; Kampmann C; Mengel KE; Kishnani PS
    Mol Genet Metab; 2011 Aug; 103(4):362-6. PubMed ID: 21605996
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [A retrospective study of six patients with late-onset Pompe disease].
    Saux A; Laforet P; Pagès AM; Figarella-Branger D; Pellissier JF; Pagès M; Labauge P
    Rev Neurol (Paris); 2008 Apr; 164(4):336-42. PubMed ID: 18439925
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prospective exploratory muscle biopsy, imaging, and functional assessment in patients with late-onset Pompe disease treated with alglucosidase alfa: The EMBASSY Study.
    van der Ploeg A; Carlier PG; Carlier RY; Kissel JT; Schoser B; Wenninger S; Pestronk A; Barohn RJ; Dimachkie MM; Goker-Alpan O; Mozaffar T; Pena LD; Simmons Z; Straub V; Guglieri M; Young P; Boentert M; Baudin PY; Wens S; Shafi R; Bjartmar C; Thurberg BL
    Mol Genet Metab; 2016 Sep; 119(1-2):115-23. PubMed ID: 27473031
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular analysis and protein processing in late-onset Pompe disease patients with low levels of acid α-glucosidase activity.
    Bali DS; Tolun AA; Goldstein JL; Dai J; Kishnani PS
    Muscle Nerve; 2011 May; 43(5):665-70. PubMed ID: 21484825
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fat and carbohydrate metabolism during exercise in late-onset Pompe disease.
    Preisler N; Laforet P; Madsen KL; Hansen RS; Lukacs Z; Ørngreen MC; Lacour A; Vissing J
    Mol Genet Metab; 2012 Nov; 107(3):462-8. PubMed ID: 22981821
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.